MTOR and cancer: The finding that MYC is downregulated by GC7 is of particular relevance, as targeting of this oncogene represents a challenging option in cancer therapy and as previous attempts to inhibit this oncogene in CRC with clinically approved translational inhibitors, such as mammalian target of rapamycin inhibitors, have failed41.